Nebibeta (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebibeta, is a beta blocker presented as an oral dosage form for oral use. It is employed to lower high blood pressure and to improve outcomes in patients with heart failure, particularly in adults and is generally well tolerated.

GNH USA supplies Nebibeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, provides batch‑specific certificates of analysis, and offers logistics support for global distribution.

Nebivolol acts on the cardiovascular system to control blood pressure and support cardiac function.

- Hypertension: lowers both systolic and diastolic blood pressure, aiding patients in reaching guideline‑recommended targets and reducing cardiovascular risk. - Heart failure: improves left ventricular ejection fraction, reduces symptoms such as dyspnea, and decreases the likelihood of hospitalization in patients with reduced‑ejection‑fraction heart failure. - Left ventricular dysfunction: enhances cardiac output and may slow progression of ventricular remodeling, supporting overall heart performance.

Nebivolol may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache - Dizziness - Fatigue - Bradycardia

Serious or Rare Side Effects: - Severe hypotension - Heart block - Bronchospasm - Allergic reactions (rash, angioedema)

When prescribing Nebivolol, clinicians should consider the following precautions to ensure safe use. - Monitor blood pressure: adjust therapy if readings remain uncontrolled. - Assess heart rate: avoid use in patients with baseline bradycardia (<60 bpm). - Caution in hepatic impairment: dose may require adjustment in moderate to severe liver disease. - Avoid abrupt discontinuation: sudden stop can precipitate rebound hypertension. - Use cautiously in asthma or COPD: β‑blockade may provoke bronchospasm. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nebivolol can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other β‑blockers: additive cardiac depression and risk of severe bradycardia. - Non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): may cause marked AV‑node block. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: combined effect may lead to excessive hypotension. - ACE inhibitors or ARBs: additive blood‑pressure lowering effect. - Digoxin: increased risk of bradyarrhythmias when used together.